David Lally to Receptors, Vascular Endothelial Growth Factor
This is a "connection" page, showing publications David Lally has written about Receptors, Vascular Endothelial Growth Factor.
Connection Strength
0.300
-
Lally DR, Loewenstein A, Arnold JJ, Yang YC, Gedif K, Best C, Patel H, Tadayoni R, Heier JS. Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies. Eye (Lond). 2023 04; 37(6):1242-1248.
Score: 0.200
-
Lally DR, Gerstenblith AT, Regillo CD. Preferred therapies for neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2012 May; 23(3):182-8.
Score: 0.100